Pricing Log in Create free account

Urogen Pharma (URGN) vs Zymeworks Inc. (ZYME)

Urogen Pharma and Zymeworks Inc. are both Biotechnology companies. Urogen Pharma and Zymeworks Inc. are of similar size ($1.8B and $1.8B). Urogen Pharma grew revenue faster over the last twelve months: 100.3% against −69.8%. Urogen Pharma has the higher net margin (−51.7% vs −404.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Urogen Pharma leads on 12 and Zymeworks Inc. on 4.

Valuation

Metric URGN ZYME Biotechnology median
P/E n/m n/m 8.50
P/S 9.23 49.29 9.71
P/B n/m 22.77 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 9.66 42.01 9.21
Earnings yield (5.73%) (8.06%) (33.15%)
Free cash flow yield (9.14%) (6.63%) (25.50%)

Profitability

Metric URGN ZYME Biotechnology median
Gross margin 90.85% (246.66%) 65.16%
Operating margin (35.32%) (418.99%) 0.00%
Net margin (51.73%) (404.00%) 0.00%
Free cash flow margin (84.32%) (324.68%) 0.00%
Return on equity 86.49% (72.31%) (56.36%)
Return on assets (42.33%) (37.25%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric URGN ZYME Biotechnology median
Revenue growth (TTM) 100.27% (69.78%) 6.02%
EPS growth (last fiscal year) (7.77%) 33.33% 30.26%
Revenue growth, 5-year CAGR 56.22% 22.16% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric URGN ZYME Biotechnology median
Debt to equity (1.45) 0.00 0.00
Current ratio 3.80 6.32 4.72
Net debt to EBITDA 0.00 2.81 0.96

Dividend

Metric URGN ZYME Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric URGN ZYME Biotechnology median
Market cap 1.79b 1.84b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack